ArticleDiabetology & metabolic syndrome2025
Association between baseline cardio-kidney-metabolic syndrome, its transition and cognitive impairment: result from CHARLS study.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- C-reactive protein-triglyceride-glucose index and incident mild cognitive impairment among patients with cardiovascular-kidney-metabolic syndrome: a dual-cohort prediction and double machine learning analysis.Journal of endocrinological investigation · 2026Article
- Baseline cardio-kidney-metabolic syndrome, its transition, and frailty: insights from the China Health and Retirement Longitudinal Study (CHARLS).European journal of medical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsCardiovascular-Kidney-Metabolic (CKM) syndrome is an integrated context encompassing diabetes, obesity, cardiovascular, and chronic kidney diseases. The impact of CKM syndrome on cognitive impairment remained unclear.
methodsThis longitudinal, observational study used data from the China Health and Retirement Longitudinal Study waves 1 and 4 (2011 to 2018). In total, 8,833 participants were included for the analysis between baseline CKM and cognitive impairment, and 4,230 were included for the analysis between CKM transition and cognitive impairment. Baseline CKM were classified into 5 consecutive stages according to the AHA statement, and transitions in CKM stages were classified as improved, stable, or progressed based on the difference in states between 2011 and 2015. Logistic regressions were used to explore the associations between CKM stages, transitions and the risk of subsequent cognitive impairment.
resultCompared with those in stage 0, the adjusted odds ratio [95% confidence intervals] (aOR [95% CI]) of incident cognitive impairment were 1.74 (1.00-3.18) for stage 1, 2.05 (1.17-3.81) for stage 2, 2.09 (1.27-3.66) for stage 3, and 3.91 (2.33-6.99) for stage 4, respectively. The odds ratios were higher among male and elder participants. In the transition analysis, the aOR (95% CI) was 0.44 (0.19-1.03) for improved group and 1.61 (1.01-2.59) for progressed group, compared with the those maintaining stable CKM stages.
conclusionsHigher CKM stages are associated with incrementally elevated risk of cognitive impairment. Additionally, the progression of CKM stages corresponded with greater hazards of cognitive impairment, while stage reversion might be associated with reduced risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.